Structured evidence table for Magnesium Glycinate Muscle Soreness Randomized Trial, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Magnesium Glycinate Muscle Soreness Randomized Trial | In the three cases, pemivibart infusion was temporally associated with rapid and meaningful improvement in fatigue associated with PEM, cognitive dysfunction, and dysautonomia, symptom clusters that often drive functional impairment in PCC. | 4 | Baratta JM (2025) | Exploring the Effects of Pemivibart Monoclonal Antibody Infusion in Long COVID: A Case Series Offering Initial Clinical Insights. |
| Magnesium Glycinate Muscle Soreness Randomized Trial | Long COVID, or post-COVID conditions (PCC), affects a substantial proportion of adults and is characterized by persistent symptoms such as fatigue, postexertional malaise (PEM), cognitive dysfunction, and dysautonomia. | 4 | Baratta JM (2025) | Exploring the Effects of Pemivibart Monoclonal Antibody Infusion in Long COVID: A Case Series Offering Initial Clinical Insights. |
| Magnesium Glycinate Muscle Soreness Randomized Trial | Pemivibart (Pemgarda), a monoclonal antibody (mAb) authorized under Emergency Use Authorization (EUA) for preexposure prophylaxis in immunocompromised individuals, has not been studied for PCC but may theoretically facilitate clearance of viral antigens. | 4 | Baratta JM (2025) | Exploring the Effects of Pemivibart Monoclonal Antibody Infusion in Long COVID: A Case Series Offering Initial Clinical Insights. |
Source documents